Boston Scientific expands its cardiac ablation catheter offerings through the $17.6 million acquisition of cryoablation technology firm CryoCor, announced April 16. The deal builds on a June 2007 collaboration between the firms for co-development of a console to power a Boston Scientific-developed cryo-ablation balloon catheter for atrial fibrillation. CryoCor's own cryoablation system, which disrupts cardiac arrhythmias using extreme cold to create lesions in cardiac tissue, was approved last August in the United States for atrial flutter. The same month, CryoCor became the first company to complete enrollment in a randomized pivotal trial for an ablation catheter to treat atrial fibrillation (1"The Gray Sheet" Feb. 4, 2008, p. 8). Boston Scientific's electrophysiology offerings, including Blazer and Chilli radiofrequency energy-based ablation catheters, are used to treat arrhythmias such as atrial flutter and ventricular tachycardia. CryoCor reported a net loss of $15.8 million in 2007 on sales of $591,000. Boston Scientific will pay $1.35 per share for the San Diego company, representing a 19.5% premium over its April 15 closing price of $1.13
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Dxcover sets up new Clinical Laboratory Improvement Amendments (CLIA) lab in Franklin, Tennessee.
EnsoData positions itself as device-agnostic and interoperable, with FDA-cleared software that can integrate with all major devices. CEO Mortara said this flexibility helps maximize patient reach by enabling both direct provider engagement and integration with device manufacturers.
After multiple warning letters and safety communications, the US FDA has decided to block the import of certain endoscopes from Olympus. In total, the agency’s action pertains to 58 device models manufactured by the Japanese firm used in urinary, respiratory, abdominal and pelvic procedures.
